[1]颜红菊,唐伦,高蕾,等.单倍体与同胞全相合造血干细胞移植治疗高危急性淋巴细胞白血病疗效观察[J].第三军医大学学报,2016,38(12):1340-1346.
 Yan Hongju,Tang Lun,Gao Lei,et al.Efficacy of haploid-matched vs sibling-matched allogeneic stem cell transplantation for high risk acute lymphoblastic leukemia[J].J Third Mil Med Univ,2016,38(12):1340-1346.
点击复制

单倍体与同胞全相合造血干细胞移植治疗高危急性淋巴细胞白血病疗效观察(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第12期
页码:
1340-1346
栏目:
专题报道
出版日期:
2016-06-30

文章信息/Info

Title:
Efficacy of haploid-matched vs sibling-matched allogeneic stem cell transplantation for high risk acute lymphoblastic leukemia
作者:
颜红菊唐伦高蕾张诚刘耀高力孔佩艳刘红张曦
第三军医大学新桥医院全军血液病中心
Author(s):
Yan Hongju Tang Lun Gao Lei Zhang Cheng Liu Yao Gao Li Kong Peiyan Liu Hong Zhang Xi

Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

关键词:
急性淋巴细胞白血病异基因造血干细胞移植移植物抗宿主病
Keywords:
acute lymphoblastic leukemia allogeneic hematopoietic stem cell transplantation graft-versus-host disease
分类号:
R329.24; R617; R733.71
文献标志码:
A
摘要:

目的      分析异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,Allo-HSCT)治疗高危急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)的疗效,并探讨临床预后因素。      方法      对我院2007年7月至2013年8月进行Allo-HSCT治疗并随访2年以上的69例ALL患者进行临床分析。按移植方式分为单倍体组(n=42)和全相合组(n=27),对各组患者的临床特征及治疗转归进行回顾性分析,应用Kaplan-Meier法进行生存分析,COX回归模型进行多因素预后分析。      结果      单倍体组2年总体生存率(overall survival,OS)及2年无白血病生存率(leukemia-free survival,LFS)分别是63.4%、59.4%,而全相合组分别是53.9%、53.7%,两组间差异均无统计学意义(P>0.05);两组间2年累积非复发死亡率(cumulative non-relapse mortality,NRM)差异也无统计学意义(P>0.05);但2年累积复发率(cumulative relapse rate,RR)单倍体组明显高于全相合组(39.5% vs 19.5%,P=0.014)。造血重建方面,单倍体组中性粒细胞植入时间明显晚于全相合移植组(P=0.002),两组血小板植入时间无明显差异(P=0.072)。单倍体组Ⅰ~Ⅱ度急性移植物抗宿主病(graft-versus-host disease,GVHD)发生率明显高于全相合组(P=0.008),两组间Ⅲ~Ⅳ度急性GVHD及慢性GVHD发生率差异无统计学意义(P>0.05)。单倍体组半年内的感染率明显高于全相合组(P=0.02)。COX多因素分析显示患者移植前的疾病状态(非CR1)为异基因移植患者的危险因素(P=0.001),其危险度为7.581;而发生局限性慢性GVHD和初诊距离移植时间较短者为预后保护因素(P=0.013和P=0.012),危险度分别为0.178和0.688。      结论      在高危组ALL患者的治疗中,单倍体Allo-HSCT与全相合Allo-HSCT的整体疗效相当,因此,单倍体供者可以作为合适的造血干细胞来源。

Abstract:

Objective      To determine the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of high risk acute lymphoblastic leukemia (ALL).      Methods      A total of 69 ALL patients treated with allo-HSCT in our center from July 2007 to August 2013 and followed up for more than 2 years after transplantation were enrolled in this study. According to transplantation types, they were divided into haploid-matched group (n=42) and sibling-matched group (n=27). Clinical characteristics and efficacy of 2 groups were retrospectively analyzed. Their survival was analyzed by the Kaplan-Meier method and the prognostic factors were analyzed with COX regression model.       Results      The 2-years overall survival (OS) and 2-year leukemia-free survival (LFS) were 63.4% and 59.4%,  in the haploid-matched group, and 53.9% and 53.7%, in the sibling-matched group(P>0.05). There was no significant difference in 2-year non-relapse mortality (NRM) between the 2 group(P>0.05), but was in 2-year cumulative relapse rate (RR), with that of haploid-matched group obviously higher than that of sibling-matched group (39.5% vs 19.5%,P=0.014). In hematopoietic reconstruction,neutrophils reconstruction was remarkably slower in the haploid-matched group than the sibling-matched group (P=0.002),but platelet reconstruction was similar(P=0.072). The incidence of grade Ⅰ~Ⅱ acute graft-versus-host disease (aGVHD) was obviously higher in haploid-matched group than sibling-matched group(P=0.008), but those of grade Ⅲ~Ⅳ aGVHD and cGVHD were similar in the 2 groups(P>0.05). The early infection incidents after HSCT (within 6 months) was obviously higher in the haploid-matched group than sibling-matched group (P=0.02).Cox regression analysis showed that disease status before transplantation (not CR1) was a main risk factor for allo-HSCT(P=0.001), with a relative risk of 7.581. The limited chronic GVHD (P=0.013)and duration from first diagnosis to transplantation (P=0.012) were protective factors, with their relative risks of 0.178 and 0.688 respectively.       Conclusion      For high-risk ALL patients,haploid-matched  and sibling-matched HSCT are similar in overall outcome, so haploid-matched donor can be suitable source for allogeneic stem cell transplantation.
 

参考文献/References:

[1]Pui C H, Robison L L, Look A T. Acute lymphoblastic leukaemia[J]. Lancet, 2008, 371(9617): 1030-1043.
[2]张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京:科学出版社, 2008.
[3]Shulman H M, Sullivan K M, Weiden P L, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients[J]. Am J Med, 1980, 69(2):204-217.
[4]Luo Y, Xiao H, Lai X, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT[J]. Blood, 2014, 124(17):2735-2743. DOI:10.1182/blood-2014-04-571570
[5]Mo X D, Xu L P, Liu D H, et al. Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT[J]. Bone Marrow Transplant, 2012, 47(9):1201-1205. DOI:10.1038/bmt.2011.250
[6]Bredeson C N, Zhang M J, Agovi M A, et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide[J]. Biol Blood Marrow Transplant, 2008, 14(9):993-1003.DOI:10.1016/j.bbmt.2008.06.009
[7]Bachanova V, Marks D I, Zhang M J, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease[J]. Leukemia, 2014, 28(3):658-665. DOI:10.1038/leu.2013.253
[8]Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2004, 10(3):195-203. DOI:10.1016/j.bbmt.2003.11.002
[9]Passweg J R, Tiberghien P, Cahn J Y, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia[J]. Bone Marrow Transplant, 1998, 21 (2): 153-158.DOI:10.1038/sj.bmt.1701064
[10]Esperou H, Boiron J M, Cayuela J M, et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society[J]. Bone Marrow Transplant, 2003, 31(10):909-918. DOI:10.1038/sj.bmt.1703951
[11]Di-Stasi A, Milton D R, Poon L M, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors[J]. Biol Blood Marrow Transplant, 2014, 20(12): 1975- 1981. DOI: 10. 1016/j.bbmt.2014.08.013
[12]Wang Y, Liu D H, Liu K Y, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center[J]. Cancer, 2013, 119(5):978-985. DOI:10.1002/cncr.27761
[13]Chao N J, Blume K G, Forman S J, et al. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Blood, 1995, 85(11):3353-3354.
[14]Chen H, Liu K Y, Xu L P, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. J Hematol Oncol, 2012, 5:29. DOI:10.1186/1756-8722-5-29
[15]Thyagu S, Minden M D, Gupta V, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol[J]. Br J Haematol, 2012, 158(4): 506-514. DOI: 10.1111/j.1365 -2141.2012.09182.x
[16]Kiehl M G, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission[J]. J ClinOncol, 2004, 22(14): 2816-2825. DOI: 10. 1200/JCO.2004.07.130
[17]Thomas E D, Buckner C D, Clift R A, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission[J]. N Engl J Med, 1979, 301(11): 597-599.
[18]Thomas E D, Sanders J E, FlournoyN, et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission[J]. Blood, 1979, 54(2):468-476.
[19]Mo X D, Xu L P, Zhang X H, et al. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups[J]. Int J Cancer, 2015, 136(7): 1697-1707. DOI:10.1002/ijc.29146
[20]Chim C S, Lie A K, Liang R, et al. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor[J]. Bone Marrow Transplant, 2007, 40(4): 339-347. DOI: 10.1038/sj. bmt.1705734
[21]Lee S, Chung N G, Cho B S, et al. Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia[J]. Leukemia, 2010, 24(12):2110-2119. DOI:10.1038/leu.2010.217

相似文献/References:

[1]陈姝,李文,罗云,等.减低剂量Bu+Cy预处理方案进行异基因造血干细胞移植治疗白血病的效果观察[J].第三军医大学学报,2012,34(24):2442.
 Chen Shu,Li Wen,Luo Yun,et al.Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen of Bu+Cy for leukemia[J].J Third Mil Med Univ,2012,34(12):2442.
[2]刘嘉,高蕾,张曦,等.异基因造血干细胞移植联合伊马替尼治疗成人Ph+急性淋巴细胞白血病临床观察[J].第三军医大学学报,2012,34(24):2453.
 Liu Jia,Gao Lei,Zhang Xi,et al.Clinical efficiency of allogenic hematopoietic stem cell transplantation combined with imatinib in treatment of Philadelphia positive acute lymphoblastic leukemia[J].J Third Mil Med Univ,2012,34(12):2453.
[3]苏毅,赖思含,易海,等.异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析[J].第三军医大学学报,2012,34(24):2456.
 Su Yi,Lai Sihan,Yi Hai,et al.Allogeneic hematopoietic stem cell transplantation for recurrent lymphoma after autologous stem cell transplantation: clinical analysis of 17 cases[J].J Third Mil Med Univ,2012,34(12):2456.
[4]梁雪,陈幸华,孔佩艳,等.异基因造血干细胞移植后肠道移植物抗宿主病临床分析[J].第三军医大学学报,2009,31(21):2158.
[5]王晓果,陈婷,刘焕凤,等.小剂量地西他滨在异基因造血干细胞移植后早期复发及cGVHD治疗中的作用[J].第三军医大学学报,2016,38(12):1362.
 Wang Xiaoguo,Chen Ting,Liu Huanfeng,et al.Role of small-dose decitabine in treatment of early recurrence and chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2016,38(12):1362.

更新日期/Last Update: 2016-06-07